God wants you to be healthy & happy!
|
|
Alzheimer's Disease Amyloid Potent Dissolver
Alzheimer's Disease, Down's Syndrome and Type II Diabetes associated Amyloid Disorders: Prevention, Treatment and Cure.
Alzheimer's disease is a leading cause of dementia in the elderly, affecting 5-10% of the population over the age of 65 years. In Alzheimer's disease, the parts of the brain essential for cognitive processes such as memory, attention, language, and reasoning degenerate, robbing victims of much that makes us human, including independence. In some inherited forms of Alzheimer's disease, onset is in middle age, but more commonly, symptoms appear from the mid-60's onward. Alzheimer's disease today affects 4-5 million Americans, with slightly more than half of these people receiving care at home, while the others are in many different health care institutions.
|
|
|
The prevalence of Alzheimer's disease and other dementias doubles every 5 years beyond the age of 65, and recent studies indicate that nearly 50% of all people age 85 and older have symptoms of Alzheimer's disease (1997 Progress Report on Alzheimer's Disease, National Institute on Aging/National Institute of Health). 13% (33 million people) of the total population of the United States are age 65 and older, and this % will climb to 20% by the year 2025 (1997 Progress Report on Alzheimer's Disease, National Institute on Aging/National Institute of Health).
|
|
Introducing CognoBlend™
CognoBlend is a potent dissolver of Alzheimers disease Amyloids. CognoBlend was discovered at University of Washington, School of Medicine. It is a proprietary blend of herbs under US patent 6,264,994 for the "Compositions for Treating Alzheimer's Disease and other Amyloidoses."
|
|
CognoBlend includes Bacopa monniera, an exotic herb that has been used by traditional ayurvedic practitioners in India since ancient times. Known as brahmi in India where it is cultivated, this powerful ingredient is known for its ability to promote thinking and reasoning. In CognoBlend it is standardized to 20 percent bacosides, the active principals known for improving memory-related function by enhancing efficacy of nerve impulses.
CognoBlend also features Ginkgo biloba extract from one of the world's oldest living trees, which has been cultivated throughout the world. Its distinctive fan-shaped leaves contain compounds that promote blood flow and therefore oxygenation in the brain. In this unique formula, Ginkgo biloba is standardized to 24 percent ginkgo flavone glycosides and 6 percent terpene lactones.
CognoBlend's proprietary formula also includes beneficial PTI-00703™ cat's claw, which is a woody vine that grows wild in the highlands of the Peruvian Amazon. PTI-00703 for mental alertness is the subject of US patent 6,264,994 , licensed exclusively to us for dietary supplement use.
Balanced with rosemary and gotu kola, CognoBlend helps promote mental sharpness, alertness and disolves Alzheimer Disease amyloids.
Previous studies involving humans have demonstrated that derivatives from either Cat's Claw or Ginkgo biloba have been well tolerated, with little to no reported side effects. Studies clearly indicated that there are unexpected synergistic effects observed by the combination of the PTI-00703 beta-amyloid protein inhibitor and Ginkgo biloba. The amyloid inhibitory ability of PTI-00703 is not altered by the addition of Ginkgo biloba.
PTI-00703™ is a trademark of ProteoTech, Inc.
|
Therapeutic Implications of PTI-00703: A Natural Plant Extract that Is a Potent Dissolver of Alzheimer's Disease Amyloid
D. McCurley*, G.M. Castillo and A.D. Snow
ProteoTech Inc. 14718 N.E. 87th St., Redmond, WA 98052-3400 and University of
Washington, Dept. of Pathology, Neuropathology Labs, Box 356480, Seattle. WA 98195-6480
Presented at the VI International Conference on Alzheimer's Disease,
Amsterdam, July 18-23, 1998
|
|
Click here to order CognoBlend!
Call 1-800-UNICITY or 1-800-864-2489
Quantity: 120 Capsules of CognoBlend
Price: $17.95 Merchant No. 409586
Specify Product No. 6003
|
|
|
|
|
Alzheimer's Disease, the Aging Population, Prevention, Treatment and Cure
Alzheimer's disease places a heavy economic burden on society. A recent study estimated that the cost of caring for one Alzheimer's disease patient with severe cognitive impairments at home or in a nursing home, is more than $47,000 per year. For a disease that can span from 2 to 20 years, the overall cost of Alzheimer's disease to families and to society is staggering. The annual economic toll of Alzheimer's disease in the United States in terms of health care expenses and lost wages of both patients and their care givers is estimated at $80 to $100 billion. Tacrine hydrochloride ("Cognex"), the first FDA approved drug for Alzheimer's disease is a acetylcholinesterase inhibitor (Cutler and Sramek, N. Engl. J. Med. 328:808-810, 1993). However, this drug has showed limited success in the cognitive improvement in Alzheimer's disease patients and initially had major side effects such as liver toxicity. The second more recently FDA approved drug, donepezil (also known as "Aricept"), which is also an acetylcholinesterase inhibitor, is more effective than tacrine, by demonstrating slight cognitive improvement in Alzheimer's disease patients (Barner and Gray, Ann. Pharmacotherapy 32:70-77, 1998; Rogers and Friedhoff, Eur. Neuropsych. 8:67-75, 1998), but is not believed to be a cure. Therefore, it is clear that there is a need for more effective treatments for Alzheimer's disease patients.
The amyloid diseases include, but are not limited to, the amyloid associated with Alzheimer's disease, Down's syndrome and hereditary cerebral hemorrhage with amyloidosis of the Dutch type, the amyloid associated with chronic inflammation, various forms of malignancy and Familial Mediterranean Fever, the amyloid associated with multiple myeloma and other B-cell dyscrasias, the amyloid associated with type II diabetes, the amyloid associated with the prion diseases, the amyloid associated with long-term hemodialysis and carpal tunnel syndrome, the amyloid associated with senile cardiac amyloid and Familial Amyloidotic Polyneuropathy, and the amyloid associated with endocrine tumors such as medullary carcinoma of the thyroid.
The inhibition of brain amyloid fibril formation and growth, disruption of preformed Alzheimer's disease amyloid fibrils, and the inhibition of PG/GAG-beta amyloid protein interactions as determined by a variety of different laboratory tests, support the use of these ingredients in combination as a dietary supplement for the inhibition and disruption of brain amyloid deposits.
Keywords: alzheimer's disease prevention cure treatment US patent cognoblend alzheimers alzheimer
|
|
